Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis
- 1 January 2009
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Neuropharmacology
- Vol. 32 (1), 41-47
- https://doi.org/10.1097/wnf.0b013e3181633497
Abstract
To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naïve patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17 cannabis-naïve patients with MS were assessed at baseline and at the end of the cannabis and placebo phases of the trial (each of 3 weeks) by means of Symptom Checklist-90 Revised, Self-rating Anxiety Scale, Multiple Sclerosis Functional Composite (of which 1 dimension is the Paced Auditory Serial Additional Test that was used to evaluate cognition), Visual Analogue Scale on health-related quality of life, Multiple Sclerosis Impact Scale-29, and Fatigue Severity Scale. Postplacebo versus postcannabinoid scores showed that no significant differences could be detected on all the variables under study. A significant positive correlation was found between Delta-9-tetrahydrocannabinol blood levels and scores at the General Symptomatic Index and at the "interpersonal sensitivity," "aggressive behaviour," and "paranoiac tendencies" subscales of the Symptom Checklist-90 Revised. No serious adverse events, abuse tendencies, or direct withdrawal symptoms were reported. Increased desire for Sativex with secondary depression was reported in 1 subject. Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-naïve patients with MS. However, the positive correlation between blood levels of Delta-9-tetrahydrocannabinol and psychopathological scores suggests that at dosages higher than those used in therapeutic settings, interpersonal sensitivity, aggressiveness, and paranoiac features might arise, although greater statistical power would be necessary to confirm this finding.Keywords
This publication has 40 references indexed in Scilit:
- Is Cannabis Use a Contributory Cause of Psychosis?The Canadian Journal of Psychiatry, 2006
- Cannabis as a risk factor for psychosis: systematic reviewJournal of Psychopharmacology, 2005
- Long-term effects of exposure to cannabisCurrent Opinion in Pharmacology, 2005
- Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young peopleBMJ, 2004
- Early adolescent cannabis exposure and positive and negative dimensions of psychosisAddiction, 2004
- The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for PsychosisNeuropsychopharmacology, 2004
- Comorbid cannabis use and panic disorder: short term and long term follow‐up studyHuman Psychopharmacology: Clinical and Experimental, 2004
- Marijuana alters the human cerebellar clockNeuroReport, 2003
- Cognitive and subjective dose-response effects of acute oral Δ 9 -tetrahydrocannabinol (THC) in infrequent cannabis usersPsychopharmacology, 2002
- A community survey of adverse effects of cannabis useDrug and Alcohol Dependence, 1996